Cavanagh Bethany J sold $5K of BEAM

Cavanagh Bethany J (SVP, Finance and Treasurer) sold 187 shares of Beam Therapeutics Inc. (BEAM) at $24.41 on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cavanagh Bethany J
Published Oct 2, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BEAM
Bearish
medium confidence
Mentioned
$BEAM
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BEAMBearishLow
01

Why it matters

The disclosed sale is small and likely has limited price impact, but signals insider activity.

02

Market read

Primary relevance is to Beam shareholders; broader market impact is negligible.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 2/10Novelty 2/10Timing: today

Background

SEC Form 4 filing discloses an insider transaction for Beam Therapeutics.

Company-level read

Ticker impact

$BEAMBearishMedium confidence
Context

Form 4 shows SVP Bethany Cavanagh sold 187 shares for $4,564, a direct insider sale via a 10b5‑1 plan.

Expected impact

potential slight downward pressure as market prices the insider sale

Evidence & confidence

The sale is modest ($5K) and executed under a pre‑arranged plan, limiting its material impact.

Market effects

Minimal impact on biotech sector; insider sales are routine.

No regional effect.

Limited to Beam Therapeutics shareholders.

Counterpoint

The sale could be a routine liquidity move and not indicative of negative fundamentals.

Key entities

  • Beam Therapeutics Inc.

    Biotech firm developing gene editing therapies.

  • Bethany J. Cavanagh

    SVP, Finance and Treasurer at Beam Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BEAMHighAI 9/10

Beam Sickle Cell Therapy Meets Pivotal Goals

Beam Therapeutics reported positive pivotal trial results for risto-cel, its sickle cell treatment, meeting all primary and secondary endpoints. The trial showed patients stayed free of severe vaso-occlusive crises for at least 12 months. Beam plans to file for FDA approval by year-end 2026, aiming to be the first base-editing therapy approved in the US. The company will present detailed results at a medical meeting in 2027.